Avicenna Alliance: enhanced knowledge, improved decisions, better outcomes
FULL MENU

Nonclinical Application Task Force

Nonclinical Application Task Force

BACK

Nonclinical Application Task Force

Mission: Promote use of in silico solutions to conduct smarter (3R’s) nonclinical studies

In silico
applications simulate real-world scenarios using computational models rather than physical experiments. Adopting nonclinical in silico applications offers several advantages in various fields, as cost-effectiveness, time efficiency, reduced dependency on animal testing, flexibility and iterative testing, risk reduction, data-driven insights, or reduced environmental impact, amongst others.

The new Nonclinical
In Silico Application task force is part of the In Silico Application (ISA) Working Group that aims to deploy in silicomethods downstream and design comprehensive solutions (process, access to research, software, hardware, humanware, possibly services) to allow any organization to time and cost effectively adopt and deploy in silico methods all along the development, registration and life cycle of the products.

The task force focuses on nonclinical applications and aims to promote use of
in silico solutions to refine, reduce or replace non-clinical studies.

Goals

  • Create an expert group among our members
  • Compile and review existing in silico solutions to reduce and refine nonclinical studies (e.g., selection of appropriate animal model(s), endpoints, time-points)
  • Promote in silico approaches to derisk nonclinical studies
  • Investigate how in silico approaches can help to ease nonclinical to clinical translation


Julien Clin

Julien Clin

Co-Chair of the Nonclinical Application Task Force

Julien Clin received his Bachelor of Engineering degree from École Polytechnique de Paris …

READ BIO
Enrico Dall'Ara

Enrico Dall'Ara

Co-Chair of the Nonclinical Application Task Force

Enrico Dall'Ara is Full Professor at the Division of Clinical Medicine of the University of …

READ BIO

NEWS

News The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)

The European Parliament voted the reform of General Pharmaceutical Legislation (GPL)

On April 10, the European Parliament overwhelmingly backed the reform of General Pharmaceutical Legislation (GPL), marking a pivotal moment in healthcare regulation. With a resounding majority, both the Directive and Regulation were embraced, reflecting a collaborative effort within the ENVI committee.

News The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!

The Avicenna Alliance warmly welcomes Tox By Design into its esteemed ranks!

Tox by Design is a prominent European toxicological expertise firm specializing in conducting toxicological Risk Assessments (RAs) for various industries such as biotech, pharmaceuticals, cosmetics, medical devices, and API synthesis.

News Marc Horner is the new Avicenna International Affairs Working Group Leader

Marc Horner is the new Avicenna International Affairs Working Group Leader

We are thrilled to announce that Marc Horner, Distinguished Engineer at Ansys, and Global Harmonization Task Force leader at the Avicenna Alliance, has been appointed as the new International Affairs Working Group Leader. Marc was already acting as a close partner of Nathalie Virag, former head of the International Affairs Working Group, recently appointed by Medtronic to prestigious responsibilities.

Sign up for our monthly newsletter!

Sign up for our monthly newsletter!

Fill in the fields you find below

Avicenna Alliance is an initiative of:

Avicenna VPH

© 2018-2024 Avicenna Alliance | powered by We Berry